Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 33.55% | 136.40% | 0.50% | 27.56% | 19.72% |
| Total Depreciation and Amortization | -3.66% | 13.96% | 15.86% | 31.86% | 16.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.22% | -38.72% | 27.84% | -38.09% | -36.94% |
| Change in Net Operating Assets | 149.67% | 448.47% | 93.17% | -43.65% | 9.50% |
| Cash from Operations | 77.42% | 411.76% | 51.97% | 2.76% | 12.10% |
| Capital Expenditure | 29.24% | -3.53% | 0.85% | 22.22% | 1.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.53% | -98.08% | -95.46% | 51.89% | 69.79% |
| Cash from Investing | -72.01% | -103.43% | -106.10% | 48.30% | 66.16% |
| Total Debt Issued | -- | -- | -- | -- | -100.31% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.53% | -83.79% | 119.50% | 56.22% | 25.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 11.12% | 6.38% | -48.94% | -48.93% | 372.73% |
| Cash from Financing | -38.16% | -88.84% | 76.00% | 32.66% | -78.30% |
| Foreign Exchange rate Adjustments | 573.07% | -423.72% | 98.53% | 197.23% | 153.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.52% | -24.60% | -134.80% | 32.09% | 24.60% |